Plasma and cerebrospinal fluid (CSF) indinavir concentrations were measured by high-performance liquid chromatography. The median concentration in plasma exceeded that in CSF 10-fold. The modeled CSF curve was flat at 155 nM, and the estimated ratio of the areas under the CSF and plasma concentration-time curves was 6%. We conclude that CSF indinavir concentrations are lower than levels in plasma but exceed the clinical 95% inhibitory concentration range.
used population pharmacokinetic (PPK) methods to estimate the IDV AUC CSF /AUC plasma ratio.
Twenty-two matched CSF and plasma samples from 22 adults were selected from the specimen bank of the HIV Neurobehavioral Research Center. All patients were at steady state on IDV-containing antiretroviral regimens and were free of opportunistic conditions. All 22 subjects took 800 mg of IDV orally every 8 h with either stavudine-lamivudine (3TC) (13 of 22), zidovudine-3TC (7 of 22), stavudine-dideoxycytosine (1 of 22) or 3TC alone (1 of 22).
Blood and CSF samples were obtained within 2 h of each other. IDV levels were measured by high-performance liquid chromatography (HPLC) at Merck Research Laboratories (West Point, Pa.). The CSF assay was validated over the range of 2.8 to 2,800 nM and had a precision of Ͻ10% of the coefficient of variation. The plasma assay was validated over the range of 7 to 2,800 nM and also had a precision of Ͻ10% of the coefficient of variation. HIV RNA levels were measured by reverse transcription-PCR (Amplicor; Roche Diagnostic Systems, Branchburg, N.J.) with a lower limit of quantitation of 50 copies/ml. Blood CD4 counts, CSF white blood cell counts, and protein levels in plasma and CSF were also determined.
PPK parameters were estimated with NONMEM software (2) using a two-compartment physiologic model (Advan4 Trans1). Monte Carlo simulations were performed to estimate model-predicted quartile concentrations. Descriptive and analytical statistics were performed using JMP software (SAS Institute, Cary, N.C.).
All patients were male. Subjects had broad ranges of CD4 counts (49 to 847 cells/mm 3 ; median, 243) and HIV RNA levels in CSF (1.7 to 3.8 log 10 copies/ml; median, 1.7) and plasma (1.7 to 5.0 log 10 copies/ml; median, 2.6). Levels of HIV RNA in plasma were approximately 1 log 10 higher than in CSF, consistent with experience in larger studies (4, 10) . The median CSF white blood cell count was 1 cell/mm 3 (range, 1 to 5) and the median protein concentrations were 7,500 mg/dl in plasma (range, 6,100 to 9,000) and 38 mg/dl in CSF (range, 26 to 120).
Median IDV concentrations were 1,491 nM (range, 40 to 11,670) in plasma and 145 nM (range, 43 to 480) in CSF. Because of falling concentrations in plasma, the CSF/plasma IDV ratio increased across the dosing interval (median, 0.16; range, 0.004 to 2.28). PPK modeling (Fig. 1 ) estimated the maximum plasma IDV concentration to be 3,500 nM. The CSF curve was flat at approximately 155 nM, likely due to slow influx to and efflux from the CSF compartment. This concen-tration approximated the modeled minimum IDV concentration (C min ) in plasma at a dose of 800 mg every 8 h. Table 1 summarizes the pharmacokinetic parameters and intersubject variability for the model. The fraction of IDV that penetrated into CSF from plasma, an estimate of the AUC CSF /AUC plasma ratio, was 6% (95% confidence interval, 5 to 9%).
The data were well described by the model with no significant biases, and modeled estimates were similar to published data (9, 14) , including substantial intersubject variability. Considering possible sources of biological, assay, and modeling variation, the calculated residual model errors were 25% for concentrations in plasma and 52% for concentrations in CSF.
All CSF IDV levels exceeded 25 nM and 12 of 22 (54%) exceeded 100 nM, the limits of the clinical IC 95 range. CSF HIV RNA levels were less than 50 copies/ml in 15 of 22 samples (68%) at the time of collection. CSF HIV RNA detection was not associated either with the specific antiretroviral regimen or with CSF IDV levels in individual patients exceeding the upper limit of the clinical IC 95 range.
Our findings are consistent with prior studies: CSF IDV levels varied little over the dosing interval and approximated both trough levels in plasma and the clinical IC 95 range. Specifically, the modeled CSF PPK curve was flat at approximately 155 nM, a level that exceeds the upper limit of the clinical IC 95 range by 55%. Despite this, the measured IDV concentrations in 10 of 22 (45%) patients were less than 100 nM. However, the clinical significance of this finding cannot be interpreted without directly measuring the IDV susceptibility of each patient's CSF viral population.
Although our HPLC-based assay measured both free and protein-bound drug, only the unbound fraction has antiviral activity. However, the low CSF-to-plasma protein ratio (1:200) probably reflects a similar ratio of drug-binding proteins, such as ␣ 1 -acid glycoprotein. With low levels of drug-binding proteins in CSF, the unbound fraction of IDV approximates the total measured concentration and may sometimes exceed the unbound fraction in plasma. For example, although the median concentration in CSF and the C min in plasma were equivalent in our model, the estimated unbound fraction in CSF (ϳ100%, or 155 nM) exceeded the estimated unbound C min in plasma (40% of 155 nM, or 62 nM) 2.5-fold.
We found that isolated CSF IDV/plasma IDV ratio measurements inadequately described CSF penetration since the ratios vary more than 100-fold depending on the postdose collection time. By estimating the AUC CSF /AUC plasma ratio through PPK modeling, we avoided the sampling bias inherent in this measure and demonstrated that CSF IDV concentrations exceed the clinical IC 95 range even though only 6% of levels in plasma enter this compartment. These CSF levels are sustained throughout the dosing interval and may contribute to the antiretroviral activity of combination regimens that contain better-penetrating agents. a The pharmacokinetic parameters and variability derived from the model were within expected ranges.
